<DOC>
	<DOCNO>NCT00755703</DOCNO>
	<brief_summary>The purpose study test recombinant vaccine safety immunogenicity healthy adult volunteer . Single dose , intranasally administer vaccine use adenovirus-recombinant vector provide safe route induce protection animal pandemic influenza preclinical study . The vaccine non-replicating , tissue culture base design intranasal delivery .</brief_summary>
	<brief_title>Safety Immunogenicity Study Adenovirus-vectored , Intranasal Pandemic Influenza Vaccine .</brief_title>
	<detailed_description>Objectives : The primary objective evaluate safety AdhVN1203/04.H5 vaccine administer intranasally two dos interval 28 day healthy adults 19-49 year age . The secondary objective evaluate immunogenicity AdhVN1203/04.H5 vaccine three different dos ( 10e8 , 10e9 10e10 viral particle ) administer intranasally two dos interval 28 day healthy adults 19-49 year age .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Adenoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male females good general health , 1949 year age Subjects must provide write consent Willing participate study completion Willing undergo nasal wash swabs provide urine blood sample per protocol safety immunogenicity analysis Female childbearing age must negative urine pregnancy test stable reliable mean contraception . Meet screen criterion hematology , chemistry urinalysis Pregnant ( possibly pregnant ) lactate woman Any flu/cold symptom and/or fever great 101 degree 3 day prior study enrollment Any intranasal steroid medication administer 10 day prior study enrollment History chronic rhinitis presence preexist nasal septal defect , nasal polyp gross abnormality Any previous nasal cautery significant surgery nasal septal defect Any regular past current use intranasal illicit drug history intravenous illicit drug use Asthma great mild severity Diagnosed active Hepatitis B C HIV positive screen Known suspect malignancy , leukemia , lymphoma Immunosuppressed , alter compromise immune status consequence disease treatment systemic corticosteroid Receipt influenza vaccine within past 6 month Receipt vaccine past 30 day Receipt investigational drug past 30 day Known Diabetes mellitus History anaphylaxis angioedema Hypertension well control Any medical , psychiatric , social condition , occupational responsibility , judgment investigator would serve interfere serve contraindication , protocol adherence , assessment safety reactogenicity , participant 's ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Pandemic</keyword>
	<keyword>Avian influenza</keyword>
	<keyword>Adenovirus strain 5</keyword>
	<keyword>Vectored vaccine</keyword>
	<keyword>Intranasal</keyword>
	<keyword>Tissue-culture derive</keyword>
	<keyword>Non-replicating</keyword>
</DOC>